Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker TXG
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 31,000 | $62.90 | $1.9M Sale | Form 4 ↗ |
| Sep 22, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 1,222 | $82.28 | $100.5K Sale | Form 4 ↗ |
| Sep 22, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 2,270 | $81.67 | $185.4K Sale | Form 4 ↗ |
| Sep 22, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 1,325 | $80.82 | $107.1K Sale | Form 4 ↗ |
| Sep 22, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 614 | $79.51 | $48.8K Sale | Form 4 ↗ |
| Sep 22, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 292 | $78.20 | $22.8K Sale | Form 4 ↗ |
| Sep 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 2,800 | $82.37 | $230.6K Sale | Form 4 ↗ |
| Sep 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 9,900 | $81.83 | $810.1K Sale | Form 4 ↗ |
| Sep 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 9,300 | $80.90 | $752.4K Sale | Form 4 ↗ |
| Sep 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 2,000 | $79.62 | $159.2K Sale | Form 4 ↗ |
| Sep 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 1,000 | $78.23 | $78.2K Sale | Form 4 ↗ |
| Sep 9, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 13,754 | $65.26 | $897.6K Sale | Form 4 ↗ |
| Sep 9, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 31,428 | $64.31 | $2.0M Sale | Form 4 ↗ |
| Sep 9, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 1,206 | $63.68 | $76.8K Sale | Form 4 ↗ |
| Sep 3, 2026 | John R. Stuelpnagel Director | TXG 10x Genomics, Inc. | Sale | 6,174 | $62.61 | $386.6K Sale | Form 4 ↗ |
| Sep 3, 2026 | John R. Stuelpnagel Director | TXG 10x Genomics, Inc. | Sale | 6,814 | $62.11 | $423.2K Sale | Form 4 ↗ |
| Sep 3, 2026 | John R. Stuelpnagel Director | TXG 10x Genomics, Inc. | Sale | 7,012 | $60.66 | $425.3K Sale | Form 4 ↗ |
| Aug 26, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 492 | $64.75 | $31.9K Sale | Form 4 ↗ |
| Aug 26, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 6,494 | $63.98 | $415.5K Sale | Form 4 ↗ |
| Aug 26, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 3,500 | $63.02 | $220.6K Sale | Form 4 ↗ |
| Aug 24, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 18,545 | $63.02 | $1.2M Sale | Form 4 ↗ |
| Aug 24, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 17,166 | $63.02 | $1.1M Sale | Form 4 ↗ |
| Aug 24, 2026 | Benjamin J. Hindson See Remarks, Director | TXG 10x Genomics, Inc. | Sale | 13,818 | $63.02 | $870.8K Sale | Form 4 ↗ |
| Aug 24, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 1,646 | $63.97 | $105.3K Sale | Form 4 ↗ |
| Aug 24, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 561 | $62.73 | $35.2K Sale | Form 4 ↗ |
| Aug 14, 2026 | Sarah A. Teichmann Director | TXG 10x Genomics, Inc. | Sale | 2,273 | $57.15 | $129.9K Sale | Form 4 ↗ |
| Aug 13, 2026 | Sarah A. Teichmann Director | TXG 10x Genomics, Inc. | Sale | 5,278 | $57.29 | $302.4K Sale | Form 4 ↗ |
| Aug 11, 2026 | John R. Stuelpnagel Director | TXG 10x Genomics, Inc. | Sale | 3,000 | $58.73 | $176.2K Sale | Form 4 ↗ |
| Aug 11, 2026 | John R. Stuelpnagel Director | TXG 10x Genomics, Inc. | Sale | 17,000 | $57.58 | $978.9K Sale | Form 4 ↗ |
| Jun 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 1,661 | $36.16 | $60.1K Sale | Form 4 ↗ |
| Jun 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 9,821 | $35.32 | $346.9K Sale | Form 4 ↗ |
| Jun 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 9,991 | $34.28 | $342.5K Sale | Form 4 ↗ |
| Jun 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 8,527 | $33.29 | $283.9K Sale | Form 4 ↗ |
| Jun 16, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 364 | $33.27 | $12.1K Sale | Form 4 ↗ |
| Jun 16, 2026 | Shehnaaz Suliman Director | TXG 10x Genomics, Inc. | Sale | 5,359 | $32.59 | $174.6K Sale | Form 4 ↗ |
| May 26, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 10,718 | $24.71 | $264.8K Sale | Form 4 ↗ |
| May 22, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 18,175 | $24.44 | $444.2K Sale | Form 4 ↗ |
| May 22, 2026 | Benjamin J. Hindson See Remarks, Director | TXG 10x Genomics, Inc. | Sale | 11,595 | $24.44 | $283.4K Sale | Form 4 ↗ |
| May 22, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 15,098 | $24.44 | $369.0K Sale | Form 4 ↗ |
| Apr 14, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 5,000 | $24.56 | $122.8K Sale | Form 4 ↗ |
| Mar 24, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 5,000 | $19.52 | $97.6K Sale | Form 4 ↗ |
| Mar 23, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 10,000 | $19.13 | $191.3K Sale | Form 4 ↗ |
| Mar 2, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 1,860 | $23.18 | $43.1K Sale | Form 4 ↗ |
| Mar 2, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 14,292 | $22.67 | $324.0K Sale | Form 4 ↗ |
| Feb 25, 2026 | Sarah A. Teichmann Director | TXG 10x Genomics, Inc. | Sale | 7,579 | $19.41 | $147.1K Sale | Form 4 ↗ |
| Feb 23, 2026 | Serge Saxonov Chief Executive Officer, Director | TXG 10x Genomics, Inc. | Sale | 9,632 | $18.58 | $179.0K Sale | Form 4 ↗ |
| Feb 23, 2026 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 8,968 | $18.58 | $166.6K Sale | Form 4 ↗ |
| Feb 23, 2026 | Benjamin J. Hindson See Remarks, Director | TXG 10x Genomics, Inc. | Sale | 7,826 | $18.58 | $145.4K Sale | Form 4 ↗ |
| Nov 24, 2025 | Adam Taich Chief Financial Officer | TXG 10x Genomics, Inc. | Sale | 11,888 | $19.00 | $225.9K Sale | Form 4 ↗ |
| Nov 24, 2025 | Benjamin J. Hindson See Remarks, Director | TXG 10x Genomics, Inc. | Sale | 8,283 | $19.00 | $157.4K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances